KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Capital Expenditures (2018 - 2024)

Esperion Therapeutics (ESPR) has disclosed Capital Expenditures for 5 consecutive years, with $189000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 159.62% year-over-year to $189000.0, compared with a TTM value of $189000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $189000.0, changed N/A over the prior year.
  • Capital Expenditures was $189000.0 for Q4 2025 at Esperion Therapeutics, up from -$317000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $189000.0 in Q4 2025 and bottomed at -$317000.0 in Q4 2024.